These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 16360289)

  • 1. The role of saturation of fat depots in the pathogenesis of insulin resistance.
    Cherian MA; Santoro TJ
    Med Hypotheses; 2006; 66(4):763-8. PubMed ID: 16360289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diabetes: insulin resistance and derangements in lipid metabolism. Cure through intervention in fat transport and storage.
    Raz I; Eldor R; Cernea S; Shafrir E
    Diabetes Metab Res Rev; 2005; 21(1):3-14. PubMed ID: 15386813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Visceral obesity, impaired glucose tolerance, metabolic syndrome, and growth hormone therapy.
    Attallah H; Friedlander AL; Hoffman AR
    Growth Horm IGF Res; 2006 Jul; 16 Suppl A():S62-7. PubMed ID: 16624603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The inflammatory consequences of psychologic stress: relationship to insulin resistance, obesity, atherosclerosis and diabetes mellitus, type II.
    Black PH
    Med Hypotheses; 2006; 67(4):879-91. PubMed ID: 16781084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The fatty acid transporter FAT/CD36 is upregulated in subcutaneous and visceral adipose tissues in human obesity and type 2 diabetes.
    Bonen A; Tandon NN; Glatz JF; Luiken JJ; Heigenhauser GJ
    Int J Obes (Lond); 2006 Jun; 30(6):877-83. PubMed ID: 16418758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adiposopathy: how do diet, exercise and weight loss drug therapies improve metabolic disease in overweight patients?
    Bays H; Blonde L; Rosenson R
    Expert Rev Cardiovasc Ther; 2006 Nov; 4(6):871-95. PubMed ID: 17173503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic implications of dietary trans-fatty acids.
    Dorfman SE; Laurent D; Gounarides JS; Li X; Mullarkey TL; Rocheford EC; Sari-Sarraf F; Hirsch EA; Hughes TE; Commerford SR
    Obesity (Silver Spring); 2009 Jun; 17(6):1200-7. PubMed ID: 19584878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of fatty acids in the pathogenesis of obesity and fatty liver: impact of bariatric surgery.
    Verna EC; Berk PD
    Semin Liver Dis; 2008 Nov; 28(4):407-26. PubMed ID: 18956297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of growth hormone on insulin resistance and atherosclerotic risk factors in obese type 2 diabetic patients with poor glycaemic control.
    Ahn CW; Kim CS; Nam JH; Kim HJ; Nam JS; Park JS; Kang ES; Cha BS; Lim SK; Kim KR; Lee HC; Huh KB
    Clin Endocrinol (Oxf); 2006 Apr; 64(4):444-9. PubMed ID: 16584518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Excess lipid availability increases mitochondrial fatty acid oxidative capacity in muscle: evidence against a role for reduced fatty acid oxidation in lipid-induced insulin resistance in rodents.
    Turner N; Bruce CR; Beale SM; Hoehn KL; So T; Rolph MS; Cooney GJ
    Diabetes; 2007 Aug; 56(8):2085-92. PubMed ID: 17519422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Free fatty acids and insulin resistance.
    Delarue J; Magnan C
    Curr Opin Clin Nutr Metab Care; 2007 Mar; 10(2):142-8. PubMed ID: 17285001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ectopic fat deposition and the metabolic syndrome in obese children and adolescents.
    Cali AM; Caprio S
    Horm Res; 2009 Jan; 71 Suppl 1():2-7. PubMed ID: 19153496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of insulin resistance, dyslipidemia, and intra-abdominal adiposity on the development of cardiovascular disease and diabetes mellitus.
    Rader DJ
    Am J Med; 2007 Mar; 120(3 Suppl 1):S12-8. PubMed ID: 17320517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin resistance--a common link between type 2 diabetes and cardiovascular disease.
    Lebovitz HE
    Diabetes Obes Metab; 2006 May; 8(3):237-49. PubMed ID: 16634983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk.
    Després JP; Lemieux I; Bergeron J; Pibarot P; Mathieu P; Larose E; Rodés-Cabau J; Bertrand OF; Poirier P
    Arterioscler Thromb Vasc Biol; 2008 Jun; 28(6):1039-49. PubMed ID: 18356555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adiponectin, insulin resistance and clinical expression of the metabolic syndrome in patients with Type 2 diabetes.
    Mojiminiyi OA; Abdella NA; Al Arouj M; Ben Nakhi A
    Int J Obes (Lond); 2007 Feb; 31(2):213-20. PubMed ID: 16755284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular mechanisms of insulin resistance and associated diseases.
    Mlinar B; Marc J; Janez A; Pfeifer M
    Clin Chim Acta; 2007 Jan; 375(1-2):20-35. PubMed ID: 16956601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in 24-h area-under-the-curve ghrelin values following diet-induced weight loss are associated with loss of fat-free mass, but not with changes in fat mass, insulin levels or insulin sensitivity.
    Purnell JQ; Cummings D; Weigle DS
    Int J Obes (Lond); 2007 Feb; 31(2):385-9. PubMed ID: 16819531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fatty liver: a novel component of the metabolic syndrome.
    Kotronen A; Yki-Järvinen H
    Arterioscler Thromb Vasc Biol; 2008 Jan; 28(1):27-38. PubMed ID: 17690317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is visceral obesity the cause of the metabolic syndrome?
    Després JP
    Ann Med; 2006; 38(1):52-63. PubMed ID: 16448989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.